A Fosfolipidni transferni protein: Veza između metabolizma lipida i inflamatornog statusa u fiziološkoj trudnoći i kardiometaboličkim komplikacijama trudnoće
Fosfolipidni transfersni protein u trudnoći
Sažetak
Uvod: Fosfolipidni transfer protein (PLTP) reguliše remodelovanje lipoproteina visoke gustine (HDL) prenosom holesterola i fosfolipida, menjajući njihovu veličinu i funkcionalnost. Trudnoća je praćena promenom u metabolizmu lipida, međutim uloga PLTP-a tokom trudnoće još uvek nije u potpunosti razjašnjena. Ova studija je ispitivala longitudinalne promene ekspresije PLTP gena koncentracije tokom zdrave trudnoće i trudnoće sa kardiometaboličkim komplikacijama, kao i njihovu povezanost sa metabolizmom lipida i inflamatornim statusom majke.
Metode: Praćeno je 84 zdravih trudnica i 20 trudnica kod kojih su se tokom trudnoće razvile gestacijski dijabetes melitus ili hipertenzivni poremećaji. Ekspresija gena za PLTP, koncentracija PLTP-a, parametri proširenog lipidnog profila i inflamatorni status analizirani su tokom trimestra.
Rezultati: Sličan tok promena ekspresije gena za PLTP i koncentracija PLTP-a uočen je u obe grupe, ali je ekspresija gena za PLTP u prvom trimestru bila značajno niža u grupi sa komplikacijama (p < 0,05). Analiza serumskih neholesterolskih sterola u HDL subfrakcijama (NCSHDL) i plazmatskih ceramida [ceramid C16:0 (Cer C16:0), ceramid C24:0 (Cer C24:0)] pokazala je značajno niže koncentracije dezmosterolaHDL (p < 0,05), kao i značajno više koncentracije C24:0 (p < 0,001) u grupi sa komplikacijama u prvom trimestru. U prvom trimestru u grupi sa komplikacijama dobijeni su i viši nivoi rezistina (p < 0,05). Ekspresija gena za PLTP u prvom trimestru bila je nezavisno povezana sa pojavom komplikacija u trudnoći.
Zaključak: Rezultati studije ukazuju na izmenjenu ekspresiju gena za PLTP, prošireni lipidni profil i inflamatorni status u prvom trimestru trudnoće sa kardiometaboličkim komplikacijama. Dobijeni rezultati naglašavaju značaj detaljnog ispitivanja metabolizma lipida i inflamatornih puteva u ranoj trudnoći u cilju unapređenja ishoda trudnoće.
Reference
2. Preda A, Preda SD, Mota M, Iliescu DG, Zorila LG, Comanescu AC, et al. Dyslipidemia in Pregnancy: A Systematic Review of Molecular Alterations and Clinical Implications. Biomedicines. 2024;12(10):2252. doi:10.3390/biomedicines12102252
3. Woollett LA, Catov JM, Jones HN. Roles of maternal HDL during pregnancy. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(3):159106. doi: 10.1016/j.bbalip.2021.159106
4. Stankovic M, Zeljkovic A, Vekic J, Antonic T, Ardalic D, Miljkovic-Trailovic M et al. Differences in HDL Remodeling during Healthy Pregnancy and Pregnancy with Cardiometabolic Complications. Antioxidants. 2024;13(8):948. doi.org/10.3390/antiox13080948
5. Settasatian N, Duong M, Curtiss LK, Ehnholm C, Jauhiainen M, Huuskonen J, Rye KA. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem. 2001;276(29):26898-26905. doi: 10.1074/jbc.M010708200.
6. Jiang XC, Yu Y. The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis. Curr Atheroscler Rep. 2021;23(3):9. doi: 10.1007/s11883-021-00907-6
7. Lee KF, Kwok KL, Chung MK, Lee YL, Chow JF, Yeung WS. Phospholipid transfer protein (PLTP) mRNA expression is stimulated by developing embryos in the oviduct. J Cell Biochem. 2005;95(4):740-749. doi: 10.1002/jcb.20444
8. Scholler M, Wadsack C, Lang I, Etschmaier K, Schweinzer C, Marsche G et al. Phospholipid transfer protein in the placental endothelium is affected by gestational diabetes mellitus. J Clin Endocrinol Metab. 2012;97(2):437-445. doi: 10.1210/jc.2011-1942
9. Scholler M, Wadsack C, Metso J, Chirackal Manavalan AP, Sreckovic I, Schweinzer C et al. Phospholipid transfer protein is differentially expressed in human arterial and venous placental endothelial cells and enhances cholesterol efflux to fetal HDL. J Clin Endocrinol Metab. 2012;97(7):2466-2474. doi: 10.1210/jc.2011-2969
10. Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP) as an emerging determinant of the adaptive immune response. Cell Mol Immunol. 2018;15(12):1077-1079. doi: 10.1038/s41423-018-0036-9
11. Taouis M, Benomar Y. Is resistin the master link between inflammation and inflammation-related chronic diseases? Mol Cell Endocrinol. 2021;533:111341. doi: 10.1016/j.mce.2021.111341
12. Augusto SN Jr, Suresh A, Tang WHW. Ceramides as Biomarkers of Cardiovascular Diseases and Heart Failure. Curr Heart Fail Rep. 2024;22(1):2. doi: 10.1007/s11897-024-00689-3
13. Youssef A, Righetti F, Morano D, Rizzo N, Farina A. Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (> 34 weeks) pre-eclampsia. Prenat Diagn 2011;31(12):1141-1146. doi: 10.1002/pd.2848
14. De Backer D, Khanna AK. The Ideal Mean Arterial Pressure Target Debate: Heterogeneity Obscures Conclusions. Crit Care Med. 2024;52(9):1495-1498. doi: 10.1097/CCM.0000000000006331
15. Vladimirov S, Gojković T, Zeljković A, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Determination of non-cholesterol sterols in serum and HDL fraction by LC/MS-MS: Significance of matrix-related interferences. J Med Biochem. 2020;39:299–308. doi: 10.2478/jomb-2019-0044
16. Antonic T, Vladimirov S, Ardalic D, Miljkovic-Trailovic M, Saric-Matutinovic M, Gojkovic T et al. Unraveling sphingolipid dynamics in late-onset preeclampsia: insights from lipidomic analysis. Biochem Med. 2025;35(1):010707. doi: 10.11613/BM.2025.010708
17. Sun M, Luo M, Wang T, Wei J, Zhang S, Shu J et al. Effect of the interaction between advanced maternal age and pre-pregnancy BMI on pre-eclampsia and GDM in Central China. BMJ Open Diabetes Res Care. 2023;11(2):e003324. doi: 10.1136/bmjdrc-2023-003324
18. Ito H, Mori T. Advanced maternal age, gestational diabetes, renal function, and obesity in hypertensive disorders of pregnancy: are we missing key risk factors? Hypertens Res. 2025;48(9):2481-2482. doi: 10.1038/s41440-025-02204-0
19. Cavoretto PI, Salmeri N, Candiani M, Farina A. Reference ranges of uterine artery pulsatility index from first to third trimester based on serial Doppler measurements: longitudinal cohort study. Ultrasound Obstet Gynecol. 2023;61(4):474-480. doi: 10.1002/uog.26092
20. Tian Y, Yang X. A Review of Roles of Uterine Artery Doppler in Pregnancy Complications. Front Med. 2022;9:813343. doi: 10.3389/fmed.2022.813343
21. Sun L, Gao B, Wang M, Liu Y, Shan Z, Teng W et al. The establishment of lipid profiles reference ranges during pregnancy: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2025;23(1):110. doi: 10.1186/s12958-025-01450-8
22. Wild R, Feingold KR. Effect of Pregnancy on Lipid Metabolism and Lipoprotein Levels. 2023, 3. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc, 2000–. PMID: 29714937.
23. Wang H, Dang Q, Zhu H, Liang N, Le Z, Huang D et al. Associations between maternal serum HDL-c concentrations during pregnancy and neonatal birth weight: a population-based cohort study. Lipids Health Dis. 2020;19(1):93. doi: 10.1186/s12944-020-01264-0
24. Jin WY, Lin SL, Hou RL, Chen XY, Han T, Jin Y et al. Associations between maternal lipid profile and pregnancy complications and perinatal outcomes: a population-based study from China. BMC Pregnancy Childbirth. 2016;16:60. doi: 10.1186/s12884-016-0852-9
25. Costa A, Reynés B, Konieczna J, Martín M, Fiol M, Palou A et al. Use of human PBMC to analyse the impact of obesity on lipid metabolism and metabolic status: a proof-of-concept pilot study. Sci Rep. 2021;11(1):18329. doi: 10.1038/s41598-021-96981-6
26. Chen L, Mir SA, Bendt AK, Chua EWL, Narasimhan K, Tan KM et al. Plasma lipidomic profiling reveals metabolic adaptations to pregnancy and signatures of cardiometabolic risk: a preconception and longitudinal cohort study. BMC Med. 2023;21(1):53. doi: 10.1186/s12916-023-02740-x
27. Melchior JT, Swertfeger DK, Morris J, Street SE, Warshak CR, Welge JA et al. Pregnancy is accompanied by larger high density lipoprotein particles and compositionally distinct subspecies. J Lipid Res. 2021;62:100107. doi: 10.1016/j.jlr.2021.100107
28. Shen X, Feng R, Zhou R, Zhang Z, Liu K, Wang S. Ceramide as a Promising Tool for Diagnosis and Treatment of Clinical Diseases: A Review of Recent Advances. Metabolites. 2025;15(3):195. doi: 10.3390/metabo15030195
29. Lantzanaki M, Vavilis T, Harizopoulou VC, Bili H, Goulis DG, Vavilis D. Ceramides during Pregnancy and Obstetrical Adverse Outcomes. Metabolites. 2023;13(11):1136. doi: 10.3390/metabo13111136
30. Juchnicka I, Kuźmicki M, Zabielski P, Krętowski A, Błachnio-Zabielska A, Szamatowicz J. Serum C18:1-Cer as a Potential Biomarker for Early Detection of Gestational Diabetes. J Clin Med. 2022;11(2):384. doi: 10.3390/jcm11020384
31. Mustaniemi S, Keikkala E, Kajantie E, Nurhonen M, Jylhä A, Morin-Papunen L et al. Serum ceramides in early pregnancy as predictors of gestational diabetes. Sci Rep. 2023;13(1):13274. doi: 10.1038/s41598-023-40224-3
32. Huang Q, Hao S, You J, Yao X, Li Z, Schilling J et al. Early-pregnancy prediction of risk for pre-eclampsia using maternal blood leptin/ceramide ratio: discovery and confirmation. BMJ Open. 2021;11(11):e050963. doi: 10.1136/bmjopen-2021-050963
33. Amraoui F, Hassani Lahsinoui H, Spijkers LJA, Vogt L, Peters SLM, Wijesinghe DS et al. Plasma ceramide is increased and associated with proteinuria in women with pre-eclampsia and HELLP syndrome. Pregnancy Hypertens. 2020;19:100-105. doi: 10.1016/j.preghy.2019.12.006
34. Klingenberg R, Leiherer A, Dobrev D, Kaski JC, Levkau B, März W et al. Ceramides in cardiovascular disease: emerging role as independent risk predictors and novel therapeutic targets. Cardiovasc Res. 2025;121(9):1345-1358. doi: 10.1093/cvr/cvaf093
35. Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP) as an emerging determinant of the adaptive immune response. Cell Mol Immunol. 2018;15(12):1077-1079. doi: 10.1038/s41423-018-0036-9
36. Audo R, Deckert V, Daien CI, Che H, Elhmioui J, Lemaire S et al. PhosphoLipid transfer protein (PLTP) exerts a direct pro-inflammatory effect on rheumatoid arthritis (RA) fibroblasts-like-synoviocytes (FLS) independently of its lipid transfer activity. PLoS One. 2018;13(3):e0193815. doi: 10.1371/journal.pone.0193815
37. Cheung MC, Brown BG, Marino Larsen EK, Frutkin AD, O'Brien KD, Albers JJ. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim Biophys Acta. 2006;1762(1):131-137. doi: 10.1016/j.bbadis.2005.09.002
38. Tan KC, Shiu SW, Wong Y, Tam S. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis. 2005;178(2):365-370. doi: 10.1016/j.atherosclerosis.2004.09.005
39. Desrumaux C, Lemaire-Ewing S, Ogier N, Yessoufou A, Hammann A, Sequeira-Le Grand A et al. Plasma phospholipid transfer protein (PLTP) modulates adaptive immune functions through alternation of T helper cell polarization. Cell Mol Immunol. 2016;13(6):795-804. doi: 10.1038/cmi.2015.75
40. Rees A, Richards O, Chambers M, Jenkins BJ, Cronin JG, Thornton CA. Immunometabolic adaptation and immune plasticity in pregnancy and the bi-directional effects of obesity. Clin Exp Immunol. 2022;208(2):132-146. doi: 10.1093/cei/uxac003
41. Taouis M, Benomar Y. Is resistin the master link between inflammation and inflammation-related chronic diseases? Mol Cell Endocrinol. 2021;533:111341. doi: 10.1016/j.mce.2021.111341
42. Mallardo M, Ferraro S, Daniele A, Nigro E. GDM-complicated pregnancies: focus on adipokines. Mol Biol Rep. 2021;48(12):8171-8180. doi: 10.1007/s11033-021-06785-0
43. Kumari R, Singh H. The Prevalence of Elevated High-Sensitivity C-Reactive Protein in Normal Pregnancy and Gestational Diabetes Mellitus. J Fam Med Prim Care. 2017;6:259-264. doi: 10.4103/2249-4863.219995
44. Woollett LA, Catov JM, Jones HN. Roles of maternal HDL during pregnancy. Biochim Biophys Acta Mol Cell. Biol Lipids. 2022;1867(3):159106. doi: 10.1016/j.bbalip.2021.159106
Sva prava zadržana (c) 2026 Aleksandra Stefanović
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.